BUZZ-Rezolute shares rise as its hypoglycemia drug meets clinical trial targets

November 13 - ** Rezolute (RZLT.O) shares surged 11.3% premarket to $4.40

** The drug development company said (link) its experimental therapy ersodetug met the primary endpoint in a late-stage clinical trial for patients with tumor-induced hyperinsulinemia

** This rare condition may cause dangerously low blood glucose levels

** RZLT reported that out of 16 enrolled patients, 13 reduced their need for intravenous glucose by at least half, and 12 were even able to discontinue the treatment entirely

** Complete results from the finished study are expected to be released in mid-December

** The therapy so far is generally well-tolerated with no safety concerns observed

** As of the previous session’s close, RZLT’s share price had risen about 64% year-to-date

(To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or may not convey the intended context, Reuters does not guarantee the accuracy of the automated translations and offers them for convenience only. Reuters accepts no liability for any loss or damages as a result of using the automated translation function.)